Older Patients With DLBCL Face Poor Overall Survival, High Costs With R-GemOx Treatment
April 1st 2024Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Read More
Review Highlights Potential for Bispecific Antibodies in DLBCL
February 28th 2024Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.
Read More
Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL
February 20th 2024A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).
Read More
Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL
February 12th 2024A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.
Read More
Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure
January 30th 2024Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
Read More
What We’re Reading: ACA Sign-Up Surge; Hospitals Fight Climate Change; Secondary Cancers, CAR T Link
January 25th 2024A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.
Read More
Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant
January 19th 2024Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.
Read More
Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL
September 21st 2023Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
Read More
Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL
September 15th 2023A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Read More
Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs
September 7th 2023The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.
Read More
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma
August 18th 2023The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.
Read More
Axi-Cel Extends Survival vs Standard of Care for R/R LBCL
August 11th 2023An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
Read More
Amid Increasing Breast Implant–Related EBV+ DLBCL Cases, Researchers Share Insights on the Disease
July 31st 2023Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).
Read More